1. Semaglutide powder Basic Information

2. Product introduction

Semaglutide is a new generation GLP-1 (Chemicalbook Glucagon-like Peptide-1) analog developed by Novo Nordisk, Denmark. Semaglutide is based on liraglutide. The long-acting dosage form developed by the drug structure has a better therapeutic effect on type 2 diabetes.

Semeglutide is a new weekly subcutaneous GLP-1 analog. Semaglutide is a 1 / w subcutaneous long-acting GLP-1 analog developed by Novo Nordisk. Compared to liraglutide, semaglutide has a longer aliphatic chain and is more hydrophobic, while semaglutide is modified with short-chain PEG and has significantly improved hydrophilicity. After PEG modification, it binds closely to albumin and can not only cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong biological half-life and achieve long circulation effects. increase.

3. Usage and dosage

The initial dose of this product is 0.25 mg, which is injected subcutaneously once a week for 4 consecutive weeks. Then increase to 0.5 mg each time. If glycemic control is poor, maintain 0.5 mg for 4 weeks. After that, once a week, the maximum dose was increased to 1 mg each time. It can be given at any time of the week, but should be at least 2 days between doses. If missed, the injection should be replenished within 5 days. For more than 5 days, the next dose should be given as originally planned.

4.Special population

The safety and efficacy of semaglutide in pediatric patients has not been established and its use is not recommended. No overall difference was observed in the safety or efficacy of semaglutide in type 2 diabetic patients, subjects 65 years and older, and young subjects, but denying the high sensitivity of individual elderly patients. you can't. sex. Patients with mild, moderate or severe hepatic or renal failure had no clinically significant dynamic differences compared to healthy subjects and did not require dose adjustment.

Currently, there is insufficient data on its use in pregnant women. Animal studies have shown that this product is reproductive toxic. The potential risk to the human body of this product is unknown. We do not recommend using this product during pregnancy. If the patient is going to become pregnant during treatment If you become pregnant, you should discontinue treatment with this product. In addition, rabbit milk contains semaglutide, so do not use this product while the patient is breastfeeding.

5. Side effects

Common side effects of semaglutide (incidence> 5%) include nausea, vomiting, diarrhea, and constipation.

6. Drug interaction

In vitro experiments confirmed that semaglutide does not inhibit or induce the CYP enzyme and does not interact with drug transporters. When used in combination with oral medications, semaglutide can cause a delay in gastric emptying and slow the rate and extent of absorption of oral medications. Semaglutide is not known to interact with metformin, atorvastatin, warfarin, digoxin, or oral contraceptives.

http://www.senwayerpeptide.com/